Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

The study will be conducted in the following 5 phases: * A no-drug Screening Phase up to 7 days in duration during which patient eligibility will be assessed; * A 6-week, open-label Run-in Phase (RIP) during which all patients will receive oral lumateperone 42 mg/day; * A 12-week, open-label Stabilization Phase (SP) during which all patients will receive oral lumateperone 42 mg/day; * A Double-blind Treatment Phase (DBTP) 26 weeks in duration during which patients receive either lumateperone 42 mg or placebo (1:1 ratio); * A 2-week Safety Follow-up (SFU) Phase.